CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

  • Myeloma Service
  • 23-182

Sorting 17 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
  • Show Principal Investigator
Sarah Cannon Research Institute at Tennessee Oncology
TriStar Centennial Medical Center
Nashville, TN
  • Accepting patients
  • Show Principal Investigator
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
  • Show Principal Investigator
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Accepting patients
  • Show Principal Investigator
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
  • Show Principal Investigator
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
  • Show Principal Investigator
Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients
  • Show Principal Investigator
147 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.